Interleukin-17 promotes angiogenesis and tumor growth

Blood

Volumn 101, Issue 7, 2003, Pages 2620-2627

  Numasaki, Muneo ^a   Fukushi, Jun Ichi ^b   Ono, Mayumi ^b   Narula, Satwant K ^b   Zavodny, Paul J ^b   Kudo, Toshio ^b   Robbins, Paul D ^b   Tahara, Hideaki ^b   Lotze, Michael T ^b  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; BLOOD CLOTTING FACTOR 8; INTERLEUKIN 17; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; RECOMBINANT CYTOKINE; RECOMBINANT INTERLEUKIN 17; UNCLASSIFIED DRUG; GROWTH PROMOTOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CORNEA; CYTOKINE PRODUCTION; ENDOTHELIUM CELL; FEMALE; FIBROBLAST; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; RETROVIRUS; T LYMPHOCYTE; TUMOR CELL; TUMOR GROWTH; TUMOR VASCULARIZATION; UPREGULATION; VASCULAR ENDOTHELIUM; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CELL DIVISION; CHEMICALLY INDUCED DISORDER; CHEMOTAXIS; CYTOLOGY; DRUG EFFECT; EXPERIMENTAL NEOPLASM; GENETICS; PATHOLOGY; RAT; UMBILICAL VEIN; VASCULARIZATION;

ANIMALS; CELL DIVISION; CHEMOTAXIS; CORNEA; ENDOTHELIUM, VASCULAR; FEMALE; GROWTH SUBSTANCES; HUMANS; INTERLEUKIN-17; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; RATS; TRANSDUCTION, GENETIC; UMBILICAL VEINS; UP-REGULATION;

EID: 0037849915     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-05-1461     Document Type: Article

References (42)

1. Folkman J, Shing Y. Angiogenesis. J Biol Chem. 1992;267:10931-10934.
2. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86:353-364.
3. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1:27-31.
4. Rouvier E, Luciani M-F, Mattei M-G, Denizot F, Golstein P. CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene. J Immunol. 1993;150:5445-5456.
5. Hymowitz SG, Filvaroff EH, Yin J, et al. IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding. EMBO J. 2001;20:5332-5341.
6. Yao Z, Fanslow WC, Seldin MF, et al. Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity. 1995;3:811-821.
7. Fossiez F, Djossou O, Chomarat P, et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med. 1996;183:2593-2603.
8. Yao Z, Painter SL, Fanslow WC, et al. Human IL-17: a novel cytokine derived from T cells. J Immunol. 1995;155:5483-5486.
9. Aarvak T, Chabaud M, Miossec P, Natvig JB. IL-17 is produced by some proinflammatory Th1/ Th0 cells but not by Th2 cells. J Immunol. 1999;162:1246-1251.
10. Jovanovic DV, Di Battista JA, Martel-Pelletier J, et al. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-1β and TNF-α, by human macrophages. J Immunol. 1998;160:3513-3521.
11. Shalom-Barak T, Quach J, Lotz, M. Interleukin-17-induced gene expression in articular chondrocytes is associated with activation of mitogen-activated protein kinases and NF-κB. J Biol Chem. 1998;273:27467-27473.
12. Awane M, Andres PG, Li DJ, Reinecker HC. NF-κB-inducing kinase is a common mediator of IL-17-, TNF-α-, and IL-1β-induced chemokine promoter activation in intestinal epithelial cells. J Immunol. 1999;162:5337-5344.
13. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long lasting anti-tumor immunity. Proc Natl Acad Sci U S A. 1993;90:3539-3543.
14. Pear WS, Nolan GP, Scott ML, Baltimore D. Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci U S A. 1993;90:8392-8396.
15. Hashimoto W, Osaki T, Okamura H, et al. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively. J Immunol. 1999;163:583-589.
16. Yoshida S, Ono M, Shono T, et al. Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol Cell Biol. 1997;17:4015-4023.
17. Kuba K, Matsumoto K, Date K, et al. HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice. Cancer Res. 2000;60:6737-6743.
18. Ohno-Matsui K, Morita I, Tombran-Tink J, et al. Novel mechanism for age-related macular degeneration: an equilibrium shift between the angiogenesis factors VEGF and PEDF. J Cell Physiol. 2001;189:323-333.
19. Green LC, Wagmer DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR. Analysis of nitrate, nitrite and [15N]nitrate, in biological fluids. Anal Biochem. 1982;126:131-138.
20. 1 and copper in angiogenesis. J Natl Cancer Inst. 1982;69:475-482.
21. 2 and angiogenesis. Proc Soc Exp Biol Med. 1983;172:214-218.
22. Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature. 1992;359:845-848.
23. + CXC chemokine-induced angiogenic activity. J Immunol. 2000;165:5269-5277.
24. Jenkins DC, Charles IG, Thomsen LL, et al. Roles of nitric oxide in tumor growth. Proc Natl Acad Sci U S A. 1995;92:4392-4396.
25. Slavin J. Fibroblast growth factors: at the heart of angiogenesis. Cell Biol Int. 1995;19:431-444.
26. Roberts AB, Sporn MB, Assoian RK, et al. Transforming growth factor type β: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci U S A. 1986;83:4167-4171.
27. Kaminski M, Auerbach R. Angiogenesis induction by CD-4 positive lymphocytes. Proc Soc Exp Biol Med. 1988;188:440-443.
28. + murine T lymphocytes, and its production declines with age. Cancer Immunol Immunother. 1988;26:31-34.
29. Brogi E, Wu T, Namiki A, Isner JM. Indirect angiogenesis cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only. Circulation. 1994;90:649-652.
30. Volpert OV, Dameron KM, Bouck N. Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity. Oncogene. 1997;14:1492-1502.
31. Cho CS, Cho ML, Min SY, et al. CD40 engagement on synovial fibroblasts up-regulates production of vascular endothelial growth factor. J Immunol. 2000;164:5055-5061.
32. Kotake S, Udagawa N, Takahashi N, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclast genesis. J Clin Invest. 1999;103:1345-1352.
33. Ziolkowska M, Koc A, Luszczykiewicz G, et al. High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. J Immunol. 2000;164:2832-2838.
34. Teunissen MB, Koomen CW, de Waal Malefyt R, Wierenga EA, Bos JD. Interleukin-17 and interferon-γ synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J Invest Dermatol. 1998;111:645-649.
35. Hirahara N, Nio Y, Sasaki S, et al. Inoculation of human interleukin-17 gene-transfected Meth-A fibrosarcoma cells induces T cell-dependent tumor-specific immunity in mice. Oncology. 2001;61:79-89.
36. Benchetrit F, Ciree A, Vives V, et al. Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood. 2002;99:2114-2121.
37. Tartour E, Fossiez F, Joyeux I, et al. Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. Cancer Res. 1999;59:3698-3704.
38. Sunderkotter C, Steinbrink K, Goebeler M, Bhardwaj R, Sorg C. Macrophages and angiogenesis. J Leuk Biol. 1994;55:410-422.
39. North RJ. Down-regulation of the antitumor immune response. Adv Cancer Res. 1985;45:1-43.
40. + T cells in mice bearing advanced sarcoma augments the antitumor action of interleukin-2. Cancer Immunol Immunother. 1994;38:107-112.
41. + CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL. J Immunol. 1999;163:184-193.
42. Gabrilovich DI, Chen HL, Girgis KR, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med. 1996;2:1096-1103.